Publications

Page 1 of 3
123

pharmacokinetics (55 POSTS)

2025 (3 POSTS)

Microphysiological systems as predictive tools for kidney nephrotoxicants: A comparison across four platforms

Sakolish C, Moyer H, Barlow N, Roe H, Tsai H, Ford L, Bajaj P, Villenave R, et al. Microphysiological systems as predictive tools for kidney nephrotoxicants: A comparison across four platforms. Abstract 3216, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

View Abstract

Comparative analysis of drug permeability and toxicity in intestinal segment-specific membrane-based barrier model using Caco-2 and human jejunal and duodenal enteroid-derived cells

Moyer H, Vergara L, Sakolish C, Stephan C, Barlow N, Roe H, Hewitt P, Villenave R, Rusyn I. Comparative analysis of drug permeability and toxicity in intestinal segment-specific membrane-based barrier model using Caco-2 and human jejunal and duodenal enteroid-derived cells. Abstract 3217, Society of Toxicology 64th Annual Meeting, Orlando, FL, March 2025.

View Abstract

Comparative analysis of the physiological and transport functions of various sources of renal proximal tubule cells under static and fluidic conditions in PhysioMimix T12 platform

Sakolish C, Moyer HL, Tsai HD, Ford LC, Dickey AN, Bajaj P, Villenave R, Hewitt P, et al. 2025. Comparative analysis of the physiological and transport functions of various sources of renal proximal tubule cells under static and fluidic conditions in PhysioMimix T12 platform. Drug Metab Dispos 53(1):10001; doi: 10.1124/dmd.124.001488. PMID: 39884810.

View Abstract

2024 (1 POST)

Analysis and comparison of nicotine pharmacokinetics of modern oral nicotine pouches

Keeton KA, Blanchette A, Benson SM, Covell LT, Madl AK. Analysis and comparison of nicotine pharmacokinetics of modern oral nicotine pouches. Poster Presentation 48 at the 77th Tobacco Science Research Conference, Atlanta, GA, September 2024.

2023 (5 POSTS)

Assessing sustainable applications of electric arc furnace steel slag as construction aggregate: Applications of probabilistic risk assessment and physiologically-based pharmacokinetic modeling

Racz L, Mittal L, Perry CS, Blanchette A, Proctor D. Assessing sustainable applications of electric arc furnace steel slag as construction aggregate: Applications of probabilistic risk assessment and physiologically-based pharmacokinetic modeling. Poster presented at Society of Environmental Toxicology and Chemistry North America 44th Annual Meeting, Louisville, KY, November 2023.

Use of physiologically based pharmacokinetic modeling to support development of an acute (24-hour) health-based inhalation guideline for manganese

Perry CS, Blanchette AD, Vivanco SN, Verwiel AH, Proctor DM. 2023. Use of physiologically based pharmacokinetic modeling to support development of an acute (24-hour) health-based inhalation guideline for manganese. Regul Toxicol Pharmacol 145:105518; doi: 10.1016/j.yrtph.2023.105518. PMID: 3786341.

View Abstract

Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

View Abstract

Analysis of reproducibility and robustness of PhysioMimix T12, a proximal renal tubule microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs and chemicals

Sakolish C, Moyer H, Fergusson SS, Chiu WA, Rusyn I. Analysis of reproducibility and robustness of PhysioMimix T12, a proximal renal tubule microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs and chemicals. Abstract 3635, Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.

View Abstract

Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates

Grover A, Sankaranarayanan S, Mathur V, Suri P, Qiu H, Andrews-Zwilling Y, Mease K, Taylor LK, Cahir-McFarland E, Keswani S, Yednock T. 2023. Pharmacokinetic and target engagement measures of ANX007, an anti-C1q antibody fragment, following intravitreal administration in nonhuman primates. Invest Opthalmol Visual Sci 64(2)3; 10.1167/iovs.64.2.3. PMID: 36729444.

View Abstract

2022 (2 POSTS)

Analysis of reproducibility and robustness of OrganoPlate® 2-lane 96, a liver microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs

Kato Y, Lim AY, Sakolish C, Valdiviezo A, Moyer HL, Hewitt P, Bajaj P, Han G, Rusyn I. 2022. Analysis of reproducibility and robustness of OrganoPlate® 2-lane 96, a liver microphysiological system for studies of pharmacokinetics and toxicological assessment of drugs. Toxicol in Vitro 85(Dec):105464; doi: 10.1016/j.tiv.2022.105464. PMID: 36057418.

View Abstract

Testing of reproducibility of a high-throughput liver microphysiological system (OrganoPlate 2-lane plate) for studies of pharmacokinetics and toxicological assessment of drugs

Kato Y, Lim A, Sakolish C, Valdiviezo A, Moyer H, Rusyn I. Testing of reproducibility of a high-throughput liver microphysiological system (OrganoPlate 2-lane plate) for studies of pharmacokinetics and toxicological assessment of drugs. Abstract 4639, Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

View Abstract

2019 (1 POST)

A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases

Ramírez-Valle F, Adams M, Beebe L, Chen J, Chuaqui C, Connarn JN, Corin AF, Dingley KH, et al. 2019. A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases. Abstract 1536, Annual Meeting of the American College of Rheumatology Conference, Atlanta, GA, November 2019.

View Abstract

2018 (3 POSTS)

Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals

Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. Environ Health Perspect 126(9):97001; doi: 10.1289/EHP1655.

View Abstract

Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium

Thompson CM, Kirman CR, Hays SM, Suh M, Harvey SE, Proctor DM, Rager JE, Haws LC, Harris MA. 2018. Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. J Appl Toxicol 38:351–365. doi: 10.1002/jat.3545.

View Abstract

Development of a physiologically-based pharmacokinetic model for the virtual high-performance aircraft pilot

Covington TR, Ott DK, Gearhart JM, Pangburn HA. Development of a physiologically-based pharmacokinetic model for the virtual high-performance aircraft pilot. Poster presented at Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

2017 (6 POSTS)

Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder

Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, … Dingley K, et al. 2017. Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorg Med Chem Lett 27(4):1094–1098; doi: 10.1016/j.bmcl.2016.12.033. PMID: 28089699.

View Abstract

Discovery of phenyl acetamides as potent and selective GPR119 agonists

Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, … Dingley KH, et al. 2017. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorg Med Chem Lett 27(5):1124–1128; doi: 10.1016/j.bmcl.2017.01.091. PMID: 28185720.

View Abstract

Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

View Abstract

Ethyl tertiary butyl ether (ETBE) and tertiary butyl alcohol (TBA) physiologically based pharmacokinetic (PBPK) model in rats: Contribution of binding to 2u-globulin and non-linear kinetics to kidney and liver responses in rats

Borghoff SJ, Ring C, Banton MI, Leavens TL. Ethyl tertiary butyl ether (ETBE) and tertiary butyl alcohol (TBA) physiologically based pharmacokinetic (PBPK) model in rats: Contribution of binding to 2u-globulin and non-linear kinetics to kidney and liver responses in rats. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

View Abstract

Using physiologically-based pharmacokinetic modeling to address potentially sensitive subpopulations exposure to hexavalent chromium

Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

View Abstract
Page 1 of 3
123